Eagle Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Eagle Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Eagle Pharmaceuticals Inc Strategy Report
- Understand Eagle Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eagle Pharmaceuticals Inc (Eagle) is a specialty pharmaceutical company that offers proprietary pharmaceutical injectables in the therapy areas of critical care, oncology, and various orphan diseases. The company’s key commercial products encompass pharmaceutical injectables, including Ryanodex for exertional heatstroke; Bendeka, and Belrapzo, both for the treatment of chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL). Pipeline products of the company include EP-4104 (dantrolene sodium) for exertional heat stroke (EHS) and nerve agent exposure; EA-114 (fulvestrant) for the treatment of breast cancer and Vasopressin injection for blood pressure. The company’s products cater to patients and healthcare professionals in the areas of critical care, orphan diseases, and oncology. Eagle Pharmaceuticals is headquartered in Woodcliff Lake, New Jersey, the US.
Headquarters
United States of America
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, New Jersey, 07677
Website
www.eagleus.com
Telephone
1 201 3265300
No of Employees
134
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
EGRX (NASD)
Revenue (2021)
$316.6M
84.6%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
513.1%
(2021 vs 2020)
Market Cap*
$58.2M
Net Profit Margin (2021)
XYZ
323.9%
(2021 vs 2020)
* As of and is in US$
Eagle Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Marketed: | Ryanodex |
| Ryanodex - Malignant Hyperthermia | Belrapzo |
| Belrapzo - Chronic Lymphocytic Leukemia & B-cell Non-Hodgkin's Lymphoma | BARHEMSYS |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Contracts/Agreements | In October, the company entered into an agreement with Eagle Pharmaceuticals to secure financial assistance for patients prescribed Eagle’s Pemfexy to manage and treat lung cancer. |
| 2023 | Contracts/Agreements | In April, the company signed an agreement with Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. related to its new drug application referencing BENDEKA. |
| 2022 | Regulatory Approval | In November, the company's investigational new drug application accepted by the US Food and Drug Administration for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjunct treatment of severe community-acquired bacterial pneumonia. |
Competitor Comparison
| Key Parameters | Eagle Pharmaceuticals Inc | Endo International Plc | CTI BioPharma Corp | Spectrum Pharmaceuticals Inc | Elite Laboratories Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Ireland | United States of America | United States of America | United States of America |
| City | Woodcliff Lake | Dublin | Seattle | Henderson | Northvale |
| State/Province | New Jersey | - | Washington | Nevada | New Jersey |
| No. of Employees | 134 | 2,931 | 128 | 86 | - |
| Entity Type | Public | Public | Private | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Graves | Chairman | Executive Board | 2016 | 60 |
| Scott Tarriff | Chief Executive Officer; President; Director | Executive Board | 2007 | 61 |
| Steven B. Ratoff | Director; Chief Financial Officer - Interim | Executive Board | 2024 | - |
| Daniel O'Connor | Executive Vice President; Head - Corporate Development; Chief Strategy Officer | Senior Management | 2019 | - |
| Ryan Debski | Chief Compliance Officer; Executive Vice President; General Counsel | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward